Alvotech Receives CRL From FDA Over Ustekinumab Filing

Knockback For Stelara Biosimilar Comes After CRLs For Adalimumab Candidate

 
• By David Wallace
  
Sign outside of FDA's headquarters in White Oak, MD
The FDA issued a complete response letter over the AVT04 candidate • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products